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INTRODUCTION 
 Pain is an unpleasant subjective sensation which can only be experienced. 
It is a fundamental biological phenomenon. The aim of anesthesiology as a 
science is the removal of pain temporarily, started initially with pain relief for 
surgeries and now extends to post-operative pain relief, relief of chronic pain 
and cancer pain. 
 The International Association for the study of pain, defines pain as an 
“unpleasant sensory and emotional experience associated with actual or 
potential tissue damage or described in terms of such damage”.1 
 A revolution in the management of acute postoperative pain has occurred 
in the past few years.  Anesthesiologists are continually in the vanguard of 
clinical and research advances in acute postoperative pain management. 
 An ideal technique should provide effective pain relief with minimal side 
effects and reasonable level of patient satisfaction in the post-operative period. 
Epidural analgesia is one of the entities practised to provide post-operative pain 
relief. 
 Central neuraxial blockade with a “combination therapy” of local 
anesthetics and non-opiates yields a near total pain relief while diminishing or 
avoiding side effects from each component alone. This newer dimension in pain 
management can be called as “balanced epidural analgesia”. It offers the most 
complete form of analgesia. 
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 Ropivacaine is a new long acting amide local anesthetic. Though it has 
similar structure, pharmacology and pharmacokinetics as that of bupivacaine it 
has lower potential for toxic effect. On milligram basis ropivacaine shows 
greater selectivity for sensory blockade and a lower systemic toxicity as 
compared to bupivacaine.2 
 Several animal and human studies report antinociceptive effects3,4,5 of 
magnesium when administered intravenously or intrathecally. Suggested 
mechanisms underlying these antinociceptive effects include the inhibition of 
calcium influx, antagonism of NMDA receptors6, and the prevention of 
enhanced ligand-induced NMDA signaling in a state of hypomagnesemia. In 
addition, magnesium seems to attenuate or even prevent central sensitization 
after peripheral tissue injury or inflammation because of inhibition of dorsal 
horn NMDA receptors. 
 It is worth studying the role of magnesium in providing perioperative 
analgesia because it is a relatively harmless molecule, inexpensive and its 
biological basis for potential antinociceptive action is promising7. 
 Although there have been many studies about magnesium, there is little 
clinical experience on its intrathecal and epidural application7. The beneficial 
effects of magnesium in literature were not unequivocal. The study was 
undertaken in the light of these data so as to evaluate the effect of magnesium as 
an adjuvant to epidural ropivacaine on the time of onset sensory and motor 
block, duration of analgesia and associated adverse effects. 
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AIM OF THE STUDY 
 
1. To compare the effects of epidural Ropivacaine and Ropivacaine with 
 Magnesium sulphate for lower limb surgeries. 
 
2. To study the effect of addition of Magnesium sulphate on the time of 
 onset and duration of action of Ropivacaine. 
 
3. To study the other effects of Epidural Magnesium sulphate. 
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REVIEW OF LITERATURE 
 
 TanmoyGhatak et al8 compared the effects of addition of  either 
Magnesium sulphate or clonidine as an adjuvant to epidural bupivacaine in 
lower abdominal and lower limb surgeries and concluded that Magnesium 
sulfate is a predictable and safe adjunct to epidural bupivacaine for rapid onset 
of anesthesia. 
 H.Birbicer and D.Avlanet al9 conducted a randomized trial to evaluate 
the role of magnesium as an adjuvant to caudal ropivacaine in children 
undergoing lower abdominal and peno-scrotal surgeries and they concluded that 
the addition of magnesium as an adjuvant to local anesthetics for caudal 
analgesia has no effect on postoperative pain and analgesic need.  
 Seong-HoonKo et al10 conducted a study which was designed to evaluate 
whether perioperative intravenous magnesium sulphate infusion affects 
postoperative pain and they concluded that perioperative iv administration of 
magnesium sulphate did not increase CSF magnesium concentration and has no 
effect on postoperative pain . 
 Bilir et al11 conducted a randomized controlled clinical trial with a 
hypothesis that the addition of Magnesium to postoperative epidural fentanyl 
may decrease the requirements for fentanyl and may improve the quality of 
analgesia and concluded that co-administration of Magnesium for postoperative 
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epidural analgesia results in reduction in fentanyl consumption without any side 
effects. 
 Tramer MR et al12  conducted a randomized double blind study to 
demonstrate the anti-nociceptive characteristics of magnesium in patients 
undergoing abdominal hysterectomy and concluded that the perioperative 
application of magnesium sulphate is associated with smaller analgesic 
requirement, less discomfort, and a better quality of sleep in the   postoperative   
period   but  not  with  adverse  effects. 
 Buvanendran et al13 studied the effect of addition of intrathecal 
magnesium to fentanyl for labour analgesia and their data indicate that 
intrathecal magnesium prolongs spinal opioid analgesia in humans and suggest  
that the availability of an intrathecal NMDA antagonist could be of clinical 
importance for pain management. 
 R.Arcioni et al14 conducted a prospective randomized, double blind, 
controlled study to evaluate the effect of combined   intrathecal   and epidural 
magnesium sulphate supplementation to reduce post-operative analgesia 
requirements in patients coming for lower limb   orthopedic surgery and 
concluded that magnesium supplementation significantly reduces postoperative 
morphine consumption. 
 Khemakhem et al 15   investigated the effect of adding magnesium to 
morphine intrathecally and recorded the quality of postoperative analgesia, 
analgesic requirement and side effects. They concluded that intrathecal 
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magnesium improved quality and duration of post-operative analgesia with 
better maternal satisfaction without additional side effects. 
 Zarauza et al16 conducted a randomized double blinded trial to test the 
ability of two L-type calcium channel blockers and Magnesium to decrease 
morphine requirement and in post-operative period for patients undergoing 
elective colorectal surgery and concluded that perioperative application of iv 
magnesium sulphate failed to decrease postoperative morphine requirement 
after colorectal surgery. 
 Tramer et al 17 conducted a randomized control trial to evaluate the 
effect of a single dose of magnesium as an adjuvant to post-operative analgesia 
and its side effects in patients undergoing ambulatory ilioinguinal hernia repair 
or varicose vein operation under general anesthesia and concluded that 
magnesium sulphate has no impact on postoperative pain and analgesic 
requirement and no difference in incidence of post-operative nausea and 
vomiting, dizziness or headache. 
 Kerdawy et al18 assessed the effectiveness of using combined 
intrathecally and epidural magnesium in reducing intraoperative and 
postoperative analgesic requirement and improving the quality of analgesia. 
They concluded that magnesium considerably reduced the perioperative 
analgesic requirement without any side effects. 
 Shashikiran et al19 evaluated the efficacy of single dose of 50 mg 
magnesium sulphate intravenously to reduce postoperative pain in patients 
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undergoing inguinal surgery. Pain at emergence from anesthesia, timing and 
dosage of rescue analgesic during first 24 hours after operation was noted. They 
concluded that preoperative magnesium sulphate infusion decreases 
postoperative pain and requirement of rescue analgesic. 
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EPIDURAL BLOCKADE 
  
History 
 CORNING has been credited with being the first to use epidural 
analgesia in 188520. Epidural analgesia has been practised by one technique or 
another since 1901 when SICARD and CATHELIN of France independently 
popularized the caudal approach in animals and was performed in man 
tentatively by KAPPIS and by BLEECK and STRAUSS. TUFFIER attempted 
epidural analgesia by the lumbar approach in the same year, with lack of 
success. 
  In 1913, HEILE approached epidural space by entering laterally through 
intervertebral foramina instead of midline puncture. In 1921 PAGES of Spain 
renewed midline lumbar approach and applied epidural analgesia in clinical 
surgery and was reintroduced by DOGLIOTTI and ADUREL in 1931. 
CURBELO of Cuba was the first worker to insert a catheter into the extradural 
space in 1949. 
Anatomy 
 Everything outside the dural sac but within the vertebral canal can be 
considered to constitute the epidural space. It is a triangular space with an 
average diameter of 0.5 cm, widest in the midline posteriorly in the lumbar 
region. The epidural space extends from the foramen magnum to sacral hiatus. 
Except in the lower sacral region it is annular in shape and narrow.  The anterior 
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and posterior nerve roots with their dural coverings pass across the very narrow 
space to unite in the intervertebral foramen to form the segmental nerves.21 
Boundaries of Epidural Space22 
 Superiorly - Foramen Magnum. 
 Inferiorly - Sacrococcygeal ligament at sacral hiatus. 
 Anteriorly - By vertebral bodies and posterior longitudinal ligaments. 
 Posteriorly   - Vertebral arches and ligamentum flavum 
Contents of epidural space 
 Dural sac 
 Spinal nerve roots 
 Extradural plexus of veins and spinal arteries 
 Lymphatics  
Epidural space has 3 functional compartments. 
1. The Cervicothoracic, which is the largest and influenced by pressure 
 changes in the superior vena cava. 
2. The Thoracolumbar which is influenced by intra-thoracic and intra-
 abdominal pressure. 
3. The Sacral canal which has no negative pressure, no pressure fluctuations 
 and does not respond to abdominal compression. 
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Indications for epidural blockade 
 Cesarean section 
 Procedures of the uterus and perineum 
 Hernia repairs 
 Genitourinary procedures 
 Lower extremity orthopedic procedures 
 Excellent choice for elderly or those who may not tolerate a general 
 anesthetic 
Contraindications 
Absolute 
 Patient refusal 
 Infection at the site of injection 
 Coagulopathy  
 Severe hypovolemia 
 Increased Intracranial pressure 
 Severe Aortic Stenosis  
 Severe Mitral Stenosis  
 Ischemic Hypertrophic Sub-aortic Stenosis  
Relative 
 Sepsis 
 Uncooperative patients 
 Pre-existing neurological deficits  
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 Demyelinating lesions 
 Stenotic valvular heart lesions (mild to moderate Aortic Stenosis) 
 Severe spinal deformities 
 
BENEFITS OF EPIDURAL ANALGESIA 
 Use of perioperative epidural anesthesia and analgesia especially with a 
local anesthetic - based analgesic solution can attenuate the pathophysiologic 
response to surgery and may be associated with a reduction in mortality and 
morbidity compared with analgesia with systemic opioids.   
 Rodgers et al23 demonstrated through a meta - analysis of randomized 
data (141 trials enrolling 9559 subjects) that perioperative use of neuraxial 
anesthesia and analgesia versus general anesthesia and systemic opioids reduced 
overall mortality by approximately 30%. Use of epidural analgesia can decrease 
the incidence of postoperative gastrointestinal, pulmonary and cardiac 
complications.   
 Christopherson et al24 demonstrated that use of intra operative regional 
anesthesia decreases the incidence of postoperative hypercoagulability related 
events (e.g. Deep vein thrombosis, pulmonary embolism. vascular graft failure). 
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Factors affecting epidural blockade 
 Several investigators have attempted to find methods to speed up the 
onset or increase the duration of epidural blockade. Adding epinephrine to the 
local anesthetic can substantially increase the duration of action of some local 
anesthetics by decreasing the vascular absorption. The effect is greatest with 2-
chloroprocaine, lidocaine, and mepivacaine, and less effective with the longer 
acting agents. Other vasoconstrictors, such as phenylephrine, have not been as 
effective in reducing the peak blood levels of local anesthetics as epinephrine. 
Alkalinization of the local anesthetic solution has been used to increase the 
speed of onset of local anesthetics. By increasing the concentration of the non-
ionic form of the drug, more drug is available to penetrate the lipid nerve cell 
membranes to produce more rapid intraneural diffusion. Adding sodium 
bicarbonate (1 mEq/10 ml of local anesthetic) immediately before injection of 
lidocaine, mepivacaine, or chloroprocaine produces a clinically significant 
faster onset of anesthesia and may provide a more complete block. Ropivacaine 
and bupivacaine will precipitate with the addition of bicarbonate unless a low 
concentration (0.1 mEq/10ml of local anesthetics) is used. 
Injection Site 
 The epidural blockade is most effective when the block or the catheter is 
inserted in a location that corresponds to the dermatomes covered by the 
surgical incision. The most rapid onset and the densest block occur at the site of 
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injection. By inserting the catheter closer to the surgical site, a lower dose of 
drug can be given, thereby reducing drug-related side effects.  
 After lumbar injection, analgesia–anesthesia spreads caudally and, to a 
greater degree, cranially. There is a delay at the L5 to S1 segments secondarily to 
the larger size of these nerve roots. With thoracic injection, the local anesthetic 
spreads evenly from the site of injection, but because of the larger nerve roots, 
there is greater resistance to blockade. By controlling the dose in the thoracic 
region, a true segmental block can be placed, affecting only the thoracic region. 
Lumbar and sacral regions will be spared, therefore, avoiding more extensive 
sympathetic blockade and subsequent associated hypotension and bladder 
dysfunction. 
Dose, Volume, and Concentration 
 The dose of local anesthetics necessary for analgesia or anesthesia is a 
function of the concentration of the solution and the volume injected. 
Concentration of the drug affects the density of the block.  
 The higher the concentration, the more profound is the motor and sensory 
block. Lower concentrations can produce a more selective sensory block. 
 Volume is the variable that affects the degree of distribution of the block. 
A larger volume will block greater number of segments. A generally accepted 
guideline in adults is 1–2 ml per segment to be blocked. This guideline should 
be adjusted for shorter patients or for the very tall.  
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 Repeat doses of local anesthetics depend on the duration of the drug. 
Doses are administered before the block regresses to the point where the patient 
experiences pain, commonly referred to as “time to two-segment regression.” 
This is defined as the time it takes for the sensory block to regress by two 
dermatome levels. When two-segment regression has occurred, one-third to 
one-half of the initial loading dose can safely be administered to maintain the 
block.  For Bupivacaine 0.5% and Ropivacaine 0.5-0.75% ,two-segment 
regression time is 180-260 minutes. 
Patient Position 
 The patient may be placed in either the lateral or sitting position 
depending on the patient’s body habitus and medical conditions. 
 The midline of the spine is easier to palpate when the patient is sitting, 
especially in the obese patient, therefore making the block technically easier. 
Whether the patient is sitting or in the lateral position, there is no significant 
difference in block height. 
Characteristics of the Patient: Age, Weight, Height, Pregnancy 
 With advancing age, the dose required to achieve the same level of block 
is reduced. The difference in block height with a fixed volume and 
concentration of local anesthetic in patients older than age 50 was between one 
to three segments higher. Greater spread in the elderly is  related to reduced size 
of the intervertebral foramina, therefore limiting the local anesthetic from 
leaving the epidural space; decreased epidural fat, allowing more of the drug to 
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bathe the nervous tissue; and changes in the compliance of the epidural space, 
leading to enhanced cephalad spread . There is little correlation between the 
spread of analgesia and the weight of the patient. However, in morbidly obese 
patients, there may be compression of the epidural space secondarily to 
increased intra-abdominal pressure, creating a higher block for a given dose of 
local anesthetic. Moreover the venous engorgement in the epidural veins 
increases the risk of entry into a vessel. 
 The correlation with height is usually not clinically significant. For short 
patients (less than or equal to 5 ft. 2 in.), the common practice has been to 
reduce the dose to 1 ml per segment to be blocked instead of 2 ml per segment. 
Bromage20 suggested a more precise dosing regimen of increasing the dose of 
local anesthetic by 0.1 ml per segment for each 2 in. over 5 ft. of height. The 
safest practice is to use incremental dosing and monitor the effect to avoid 
excessively high anesthetic levels. 
 Pregnancy causes an increased sensitivity to both regional and general 
anesthetics, although the studies regarding the causes have been conflicting. The 
most recent studies attribute the sensitivity of pregnant women to regional and 
general anesthetics to levels of progesterone or increased concentrations of 
endorphins, causing an increase in the pain threshold. 
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Side effects and Complications 
Complications of puncture 
1. Subcutaneous and intramuscular injections. 
2. Injection into paravertebral space. 
3. Injury to intervertebral discs and ligaments. 
4. Injury to blood vessels and paraplegia. 
5. Dural puncture 
6. Damage to spinal cord or nerve roots. 
Complications and toxicity related to injected solutions 
1. Intravascular injection. 
2. Subarachnoid injection. 
3. Subdural injection. 
4. Hemodynamic alteration. 
Complete or partial failure of block 
1. Complete failure of the block. 
2. Lateralization of the block. 
3. Unanaesthetised dermatomes. 
4. Inappropriate height of the block. 
 Other complications are sensory disturbance and problems of sphincter 
control, sudden loss of consciousness due to rapid injection of large volume 
leading to sudden increase in ICP, infection and chemical meningitis, vomiting 
and shivering. 
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Assessment of epidural blockade 
Sensory block - Testing for loss and return of pin-prick sensation 
(partial sensory block) in each dermatome on both sides of the body. 
‐ Assessing loss of temperature sensation (most sensitive indicator of initial 
 onset of sensory block) using an alcohol swab is another method. 
‐ Complete loss of touch sensation may also be charted. 
Somatosensory Evoked Potentials 
 Cortical derived Somatosensory Evoked Potentials have been used in the 
qualitative assessment of intensity of peripheral and central neuronal blockade. 
Somatosensory Evoked Potentials reflects the net results of neuronal activities 
coming from the peripheral nerves through the spinal cord to the brain. 
Somatosensory Evoked Potentials are generated by repetitive stimulation of 
peripheral nerves. Intraoperative monitoring of Somatosensory Evoked 
Potentials is a technique to assess the functional integrity of sensory pathways, 
particularly in spinal and scoliosis surgeries. 
 Total afferent blockade is often not obtained even though a clinically 
adequate block is achieved as assessed by Pin-prick sensation following 
epidural administration of Bupivacaine, Mepivacaine and Etidocaine. 
Abolishment of Somatosensory Evoked Potentials has only been accomplished 
using 1.5% Etidocaine as this has the ability to penetrate the white matter of 
spinal cord more readily. 
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Sympathetic block 
‐ Assessment by measuring skin temperature with a telethermometer 
 thermography or temperature sensitive paper. 
‐ Digital plethysmogram may also be used. 
‐ Skin conductance can be measured using psychogalvanic response. Sweat 
tests such as cobalt blue and starch iodine or the response of skin 
plethysmography to ice during venous occlusion plethysmography are used for 
research purposes.  
Motor Block 
Assessed using Bromage Scale20  for motor block in lower limbs. 
BROMAGE SCALE 
No Block (0 %) Full flexion of knees and feet possible. 
Partial (33%) 
Just able to flex knees, still full flexion of feet 
possible. 
Almost complete (66%) 
Unable to flex knees. Still flexion of feet 
possible. 
Complete (100%) Unable to move legs or feet 
 
 Motor block in lower limbs can be assessed with reference to specific 
myotomes. A score of ‘0’ is assigned for no block and ‘1’ for complete block 
(no movement) at each joint on each side. Thus maximal motor block is 
represented bilaterally with a score of 10. 
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An onset profile for motor block can be represented as a “Myotomes score-
time” diagram. An apparatus (Axelsson) that measures maximal isometric 
strength by a force transducer at ankle, knee and hip can be used for research 
purposes which provide objective, reproducible measurements of muscle power.  
Abdominal muscle power may be assessed by the rectus abdominis muscle 
(RAM) test. This is useful in abdominal surgery when abdominal muscle 
blockade is required rather than lower limb muscle blockade.  
RAM TEST OF ABDOMINAL MUSCLES 
100% power Able to rise from supine to sitting position with hands 
behind head. 
80% power Can sit only with arms extended. 
60% power Can lift only head and scapulae off the bed. 
40% power Can lift only shoulders off the bed. 
20% power An increase in abdominal muscle can be felt during effort; 
no other response. 
 
Both scales may be used when a comprehensive picture is required: RAM test 
(T5 –T12) and Bromage scale (L1-S2). 
Electromyography 
 Few studies have used the more quantitative method of electromyography 
(EMG) which would give more sensitive assessment. 
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Reflex response 
 Under general anaesthesia without muscle relaxation, sensation can still 
be crudely assessed by use of reflex response to pinch by a forceps at 
appropriate segmental levels. Alternatively, the tendon reflexes in the lower 
limbs give a gross index of both motor and sensory block while reflexes such as 
cremaster, anal and abdominal muscles may also help in assessing adequacy of 
blockade. 
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EPIDURAL ADJUVANTS 
 The use of adjuvant drug is aimed at prolonging the analgesia of the local 
anesthetics, making it possible to avoid toxic dosage and to obtain a prolonged 
analgesia. 
ADRENALINE 
 It was for many years the only adjuvant drug available and even today it 
is used in many cases. The 1 : 200,000 or 100,000 concentrations allows 
vasoconstriction of  peridural vessels reducing the uptake of local anesthetics; 
thus the drug concentration in action sites is increased and at the same time the 
plasma concentration and drug toxicity are decreased. It increases the intensity 
of motor blockade. However the validity of adrenaline is not universally agreed 
upon. Infact this drug acts mainly with short duration local anesthetics as 
lidocaine and mepivacaine, whereas it is not effective in association with 
bupivacaine which fixes more permanently with peridural fat. 
 Moreover, adrenaline has recently been debated as the possible cause of 
severe neurological damages in infants attributable to spinal cord ischemia and 
subsequent paraplegia. 
OPIOIDS   
 They act at the level of the receptors localized mainly in the substantia 
gelatinosa of dorsal horns of the spinal cord and are used for peridural 
anesthesia. Opioids act by inhibiting the release of Substance P and glutamate 
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from the sensory neurons pre-synaptically at the level of A delta and C fibers 
and by hyperpolarizing the postsynaptic membrane. 
 These drugs are not commonly used due to their side effects that are 
present even in case of peridural administration and include nausea, vomiting, 
pruritus and urinary retention. However, the main adverse reaction is respiratory 
depression, caused by the central action of these drugs and appearing as in the 
case of morphine, even after 6 – 8 hours. 
KETAMINE 
 This potent anesthetic has recently been considered for epidural 
administration.  Ketamine acts at the level of NMDA receptors (present in the 
spinal cord and involved in nociceptive modulation in central nervous system, 
in wind up sensitization and hyperalgesia) as antagonist and thus producing 
analgesia. Ketamine depresses the excitation of spinal wide dynamic range 
neurons by acting at the spinal as well as supra spinal level. 
Dosage: 0.25 to 0.5 mg/Kg body weight 
CLONIDINE 
 The use of  α2 agonists particularly of clonidine is, as in the case of 
Ketamine, more recent with respect to opioids and adrenaline. It has always 
been used as an antihypertensive drug, but today it has proved to provide a good 
analgesia. This characteristic is largely described in adults where clonidine is 
added to local anesthetics or opioids, in extradural or intrathecal anesthesia, for 
postoperative pain control, and acts mainly at the level of dorsal horns of spinal 
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cord. It has agonistic activity at spinal α2 receptors through cholinergic 
mechanism (acetyl choline release). Spinal cord dorsal horn levels of 
norepinephrine and acetyl choline are increased following spinal clonidine, 
producing inhibitory modulation of nociceptive input at the level of spinal cord. 
Hypotension following its use is common and should be anticipated. 
Dosage: 0.5 to 2 microgram/kg/hr by continuous infusion. 
DEXMEDETOMIDINE 
 The use of  Dexmedetomidine as adjuvant in regional anesthesia is still 
not validated. Maarouf73 explored the effects of epidural dexmedetomidine on 
the incidence of postoperative shivering in patients undergoing orthopedic 
surgery. He found that in patients who received Dexmedetomidine at a dose of 
100 microgram added to 20 ml 0.5 % Bupivacaine, showed lower incidence in 
postoperative shivering when compared to patients who received epidural 
bupivacaine alone (10% vs 36%). 
NEOSTIGMINE 
 Cholinergic system is thought to modulate pain perception and 
transmission by spinal mechanism. Acetyl choline is one of more than 25 
neurotransmitters that participate in the spinal cord’s modulation of pain 
processing. Mainly muscarinic receptors play a part in producing analgesia. 
Analgesia by neostigmine is not associated with respiratory depression but a 
significant incidence of nausea, vomiting and more rarely anxiety has been 
noted to occur. 
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  Epidural neostigmine 1- 4 micrograms added to a local anesthetic 
solution produces a dose dependent analgesic effect in patients after minor 
orthopedic procedures. 
 Other agents such as tramadol, droperidol, and midazolam have been 
studied with various effectiveness in epidural analgesia. Considerable 
controversy surrounds the use of midazolam intrathecally. Despite multiple 
publications recommending its use intrathecally, recent studies have 
demonstrated that even a single dose of intrathecal midazolam may have 
neurotoxic effects on the neurons and myelinated axons. Until its safety profile 
can be ensured in human subjects, it is not recommended for use intrathecally or 
epidurally at this time. 
 One agent showing promise is a new formulation of one of the oldest 
opioids, morphine. Epidural morphine has proven analgesic efficacy without the 
bothersome side effects of intravenous dosing. Pain relief with single epidural 
injection lasts less than 24 hours, requiring the institution of alternate methods 
to provide pain relief. Depodur, the brand name for extended-release epidural 
morphine, uses a drug-release delivery system called Depofoam. Depofoam is 
composed of microscopic lipid-based particles with internal vesicles that 
contain the active drug and slowly release it. Recent studies of Depofoam have 
demonstrated effective pain relief with minimal side effects for up to 48 hours. 
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PHARMACOLOGY OF ROPIVACAINE 
 Introduced in 1992,  Ropivacaine is a new long acting amide local 
anesthetic.  Ropivacaine has a propyl group and bupivacaine has a butyl group 
on the piperidine nitrogen atom of the molecule which was synthesized in 1957. 
Though it has similar structure, pharmacology and pharmacokinetics as that of 
bupivacaine,  Ropivacaine has lower potential for toxic effect . Ropivacaine is a 
pure (s-isomer) enantiomer. On milligram basis, Ropivacaine shows greater 
selectivity for sensory blockade and a lower systemic toxicity as compared to 
bupivacaine. 
Chemical name: (S)-1propyl 2’,6’pipecoloxylidide hydrochloride monohydrate 
Formula: C17H26N2O 
Physicochemical properties: 
Molecular mass    : 274.4 gm/mol 
pKa     : 8.1 
Solubility in water at 250C  : 53.8 g/L 
Protein binding    : 94% 
Volume of distribution   : 41 L 
Mechanism of action 
 Ropivacaine reversibly interferes with the entry of sodium ion to the 
nerve cell membranes, leading to decreased membrane permeability to sodium 
and raises the threshold for electrical excitability. The order of blockade 
affecting the nerve fibers is: autonomic, sensory and motor; and the effect 
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disappears in the reverse order. Clinically the order of loss of sensations is: 
pain, temperature, touch, motor and proprioception. 
Pharmacokinetics 
 It has bioavailability of about 87% - 98% when administered epidurally.  
The absorption depends on the total dose, route, concentration of the drug and 
the patient’s hemodynamic condition and the vascularity of the administration 
site. The onset of action begins at 10 - 25 minutes after epidural administration, 
5 minutes after spinal administration, 15 –30 minutes after major nerve block 
and 1 – 15 minutes after field block. 
 Ropivacaine is extensively bound to plasma proteins (94%), mainly α 
acid glycoprotein and the systemic toxicity is related to unbound drug 
concentration. It crosses the placenta. It is metabolized by Cyt P450 1A; by 
aromatic hydroxylation to 3’OH Ropivacaine and 4’OH Ropivacaine. It has a 
half-life of about 1.6 – 6hours which varies with route of administration. 86% of 
the drug is eliminated in the urine. It has greater clearance and shorter 
elimination half-life as compared to bupivacaine. It also has decreased lipid 
solubility and decreased volume of distribution as compared to bupivacaine. 
Uses 
 Ropivacaine is indicated for local anesthesia including infiltration, nerve 
block, epidural and intrathecal anesthesia in adults and children. It is also 
indicated for peripheral nerve block and caudal epidural in children for surgical 
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pain. It is also sometimes used for infiltration anesthesia for surgical pain in 
children. 
Adverse effects 
 Mostly they are related to administration techniques resulting in systemic 
exposure or pharmacologic effects of anesthesia. Allergic reactions can also 
occur. Systemic exposure to excessive quantities of ropivacaine mainly results 
in CNS and CVS effects. CNS effects usually occur at lower plasma 
concentration. 
CNS effects 
 It may include CNS excitation (nervousness, tingling around the mouth, 
tinnitus, tremor, dizziness, blurred vision, seizures) followed by depression 
(drowsiness, loss of consciousness, respiratory depression and apnea). 
CVS effects 
 It includes hypertension, bradycardia, arrhythmias and or cardiac arrest- 
some of which may be due to hypoxemia secondary to respiratory depression. 
As for bupivacaine there is evidence that Intralipid, a commonly available 
intravenous lipid emulsion, can be effective in treating severe cardiotoxicity. 
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PHARMACOLOGY OF MAGNESIUM 
 Magnesium is the fourth most abundant essential cation in the human 
body and plays a fundamental role in many cellular functions such as storage, 
metabolism and energy utilisation25.  
CLINICAL USES:  
1) Magnesium and Anesthesia: At the beginning of last century, 
magnesium was proposed to induce anesthesia effectively26. Magnesium has 
been suggested for reducing anesthetic requirements, attenuating cardiovascular 
effects from laryngoscopy and intubation and exerting muscle relaxing 
effects27,28.  A competitive antagonism on hippocampal  presynaptic calcium 
channels that regulate neurotransmitter release in the central nervous system is 
responsible for the anesthesia enhancing effects of magnesium29. Attenuation of 
catecholamine release from the adrenal medulla and calcium antagonistic effects 
on vascular smooth muscle cells may also contribute to the anesthetic effects of 
magnesium. In terms of neuromuscular blockade the inhibition of calcium 
mediated release of Acetyl choline from presynaptic nerve terminals at the 
neuromuscular junction plays an important role. A decrease of postsynaptic 
sensitivity to acetyl choline and direct effects on the membrane potential of 
myocytes may also contribute30.  
2) Magnesium and Analgesia: Several animal and human studies report 
antinociceptive effects of magnesium when administered intravenously and 
intrathecally11,13,29-33. Suggested mechanisms underlying these antinociceptive 
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effects include the inhibition of calcium into the cell via noncompetitive 
blockade of N-methyl-D-aspartate (NMDA receptor)34.  Magnesium and 
NMDA receptors are thought to be involved in the modulation of pain35. 
Magnesium is also physiological calcium antagonist at different voltage gated 
channels which may be important in the mechanism of antinociception. 
Magnesium seems to attenuate or even prevent central sensitization after 
peripheral tissue injury or inflammation because of inhibition of dorsal horn 
NMDA receptors36, 37.  
3) For Severe Preeclampsia and Eclampsia: Preeclampsia is defined as 
new onset hypertension and proteinuria developing after 20 weeks of gestation 
upto several weeks after delivery and it may be aggravated by seizures or 
trauma. It is a major cause of maternal and fetal morbidity and 
mortality38.Magnesium seems to improve clinical symptoms of preeclampsia 
and eclampsia by systemic cerebral and uterine vasodilatation. In addition it 
increases concentration of two endogenous potent vasodilators, Endothelium 
derived relaxing factor and Calcitonin gene related peptide and also attenuates 
circulating concentrations of Endothelin-1 an endogenous vasoconstrictor39,40. 
Magnesium remains the most commonly used drug for preeclampsia and 
eclampsia since its approval in the early 1990s41. There is Class I level of 
evidence A recommendation (AHA) for the use of magnesium as an 
anticonvulsant in severe preeclamptic or eclamptic women. Magnesium should 
be administered intravenously using a loading dose of 4-6gm diluted in 100ml 
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of normal saline given over 20-30 minutes and subsequent maintenance dose of 
1-2 gm per hour. The infusion should be continued at least 24 hours after 
delivery42.  
 To avoid serious adverse effects, respiration, presence of tendon reflexes 
and urine output should be closely monitored during treatment43.  
4) Preterm birth and fetal neuroprotection: Magnesium has been used as 
a tocolytic agent to attenuate uterine contractility by decreasing intracellular 
calcium concentration and subsequent inhibition of myosin light chain kinase44. 
But results of clinical trials have not been convincing. However, antenatal 
administration may be considered because there is level A evidence (AHA) 
showing its neuroprotective effects in preterm neonates45.  
5) Stress attenuation: To reduce the stress response during intubation, 
magnesium sulphate is used in the dosage of 30-50mg/kg intravenously27.  
6) Magnesium and Phaeochromocytoma: Several case reports have 
described the successful use of magnesium during Phaeochromocytoma crisis. It 
helps to maintain hemodynamic balance because it inhibits the catecholamine 
release from adrenal medulla and adrenergic nerve endings, direct blockade of 
catecholamine receptors and vasodilation and antiarrhythmic properties related 
to L type calcium channel antagonism46-48. 
7) Magnesium and Asthma or COPD: Magnesium induced 
bronchodilation may be mediated by several pathways: attenuation of calcium 
induced muscle contraction, inhibition of cholinergic neuromuscular 
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transmission, anti-inflammatory activity, potentiation of beta agonist on 
adenylcyclase, reversal of magnesium depletion after beta adrenergic 
treatment49-51. In patients with life threatening exacerbations of asthma and 
those in whom exacerbations remain in the severe category after 1 hour of 
intensive conventional therapy; the administration of magnesium sulfate can be 
considered52 Class II level of evidence A (AHA). There is little evidence to 
recommend the routine use of magnesium in patients with COPD. 
8) Magnesium and cardiac arrhythmias: Even though not a classic 
antiarrhythmic drug it may convert some malignant arrhythmias. Accordingly 
low magnesium serum concentrations were shown to be potentially pro-
arrhythmogenic. Magnesium slows electrical activity of the SA node, prolongs 
AV conductance and finally increases the refractory period of AV node. 
Torsade de pointes tachycardias certainly benefit from administration of 
magnesium. Malfunction of potassium channels result in delayed ventricular 
repolarization and inactivation of calcium channels53. The late calcium influx 
combined with prolonged repolarization causes early after depolarization 
leading to Torsade de pointes and associated long QT intervals54. Magnesium 
attenuates these pathological changes by inhibiting calcium currents. 2 grams 
magnesium sulfate should be the drug of choice followed by electrolyte 
stabilization and efforts to accelerate the basic heart rate55-58. 
 Magnesium is well established in the management of Digoxin induced 
tachyarrhythmias59 and atrial fibrillation after cardiac surgery60. 
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9) Magnesium and myocardial infarction:  Magnesium was found to 
induce coronary and systemic vasodilation to improve metabolism of 
cardiomyocytes and to attenuate ischemia / reperfusion injury to the myocardial 
tissue61-63. These protective effects have been ascribed to calcium antagonism 
because calcium overload is the leading cause of myocardial cell death64. 
Magnesium prolongs the absolute refractory period and shortens the relative 
refractory period; thereby reducing the incidence of infarction related 
arrhythmias65.Magnesium was reported to have beneficial effects on the 
incidence of cardiac arrest after refractory ventricular fibrillation.  
SIDE EFFECTS 
 Intravenous administration of magnesium is associated with minor side 
effects. It may provoke burning sensation or pain on injection and induce 
agitation drowsiness and nausea. Patients may also experience headache, 
dizziness and muscle weakness, hypotension and bradycardia66. In eclampsia, 
approximately 25% of women treated with magnesium experience side effects 
mainly flushing67. Magnesium may increase the risk of post-partum hemorrhage 
and respiratory depression42. Because magnesium crosses the placenta it may 
induce neonatal lethargy, hypotension and rarely respiratory depression after 
prolonged administration.  
 In 2 cases reported by Goodman and colleagues68, larger doses (8.7 gms, 
9.6 gms) of magnesium inadvertently administered into the epidural space did 
not cause any neurological injury. Another report described an inadvertent 
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intrathecal injection of 1000 mg of magnesium producing a transient motor 
block followed by a complete resolution and no neurological deficit at long term 
follow up69. 
PREPARATIONS AVAILABLE:  
Parenteral injection: Magnesium sulphate -    10%, 12.5%, 50%  
For Intravenous use only    -    4%, 8%.  
Magnesium sulphate in dextrose:                1% in 5%dextrose.  
       2% in 5% dextrose. 
 When administered intravenously the onset of action is immediate and 
duration of action is 30 min. On administration by intramuscular route the onset 
of action takes 1hr and duration of action is 3-4 hrs.  
Storage: 15-30 degree centigrade. For IV use concentration of 20% or less 
should be used. Rate of injection should be 1.5ml/hr.  
DRUG INTERACTIONS:  
Drug Interaction 
Antibiotics Mg decrease absorption of quinolone and 
tetracycline. 
Aminoglycoside lower Mg serum 
concentration. 
Antidiabetics Mg increase absorption of Glipizide and 
Glyburide. 
Calcium channel blocker Calcium may enhance hypotensive effects 
Digoxin Mg decreases effect of digoxin. 
Digoxin increases renal excretion of Mg. 
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Diuretics Loop and thiazide diuretics may lower Mg 
serum concentration 
Neuro-muscular blocker Mg enhances the neuromuscular blockade. 
 
SYMPTOMS AND TREATMENT OF OVERDOSE:   
 Magnesium intoxication is manifested by a sharp drop in blood pressure 
and respiratory paralysis. Disappearance of the patellar reflex is a useful clinical 
sign to detect the onset of magnesium intoxication. In the event of overdosage, 
artificial ventilation must be provided until a calcium salt can be injected i.v to 
antagonize the effects of magnesium.   
 In adults, i.v. administration of 5 to 10 mEq of 10% calcium gluconate 
will usually reverse respiratory depression or heart block due to magnesium 
intoxication. In extreme cases, peritoneal dialysis or hemodialysis may be 
required. 
 Hypermagnesemia in the newborn may require resuscitation and assisted 
ventilation via endotracheal intubation or intermittent positive pressure 
ventilation, as well as i.v. calcium.  
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MATERIALS AND METHODS 
  This study was done at the operation theatre complex attached to the 
Department of Anesthesiology, Tirunelveli Medical College Hospital,  
Tirunelveli from January to April 2011. 
STUDY DESIGN: Randomized Prospective comparative study. 
INCLUSION CRITERIA :Patients between (16-60yrs) of either gender 
belonging to American Society of Anesthesiologists status I and II with  + 20% 
of ideal body weight and height undergoing lower limb surgeries. 
EXCLUSION CRITERIA: 
1. Hepatic, renal or cardiovascular dysfunction. 
2. Patients in whom central neuraxial block is contraindicated. 
3. History of hypersensitivity/ adverse reaction to any of the study 
  medication. 
4. History of chronic analgesic use. 
5. Chronic pain syndrome. 
6. Cases where communication difficulties prevent reliable  
  assessment. 
7. Psychological disorders. 
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Preoperative evaluation: 
 In all the patients, age, sex and the baseline vital parameters were 
recorded. History regarding previous anesthesia, surgery and any significant 
medical illness, medications and allergy were recorded. Complete physical 
examination and airway assessment were done. 
Following laboratory investigations were done. 
 Hemoglobin % 
 Blood sugar and urea 
 Serum creatinine 
 Bleeding time & Clotting time 
 Chest X  Ray & ECG 
 All the patients were educated about the 10 point visual analogue pain 
scale (VAPS) at the pre-operative visit. 
STUDY METHOD: 
  After obtaining institutional ethical committee approval and written 
informed consent, 60 patients were randomly selected and allocated into two 
groups. 
 Group R (n=30): 0.75% Ropivacaine (16ml) + 0.9% saline (1ml) 
 Group RM (n=30): 0.75% Ropivacaine (16ml) + Magnesium sulfate 
 (1ml) 50mg 
 After establishing an intravenous access, an infusion of ringer’s lactate 
(20 ml/kg) comprised preloading. Standard monitoring was instituted after 
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shifting the patient on the operating table. Baseline measurements of pulse rate, 
blood pressure and SpO2 were recorded. They were positioned in the sitting or 
left lateral position on a horizontal table. Under strict aseptic precautions, using 
an 18G Tuohy needle, the epidural space was identified at the L2-3 or L3-4 space 
using a loss of resistance to air technique. A 20 G epidural catheter was then 
advanced for 5 cm into the epidural space. A standard test dose of 3 ml of 
lignocaine 1.5% with adrenaline (1:2,00,000) was given to verify the correct 
placement of the catheter.  
 Syringes containing the study drug was prepared and loaded by another 
anesthesiologist who did not participate in the study.   The patient, the person 
who administered the drug and the observer were unaware of the content of the 
syringes. 
 After administering the test dose the patient received the appropriate 
study drug epidurally, slowly over 5 minutes. 
 The following parameters were monitored  Heart Rate, Noninvasive 
Arterial Blood Pressure, SPO2were recorded every 5 min for the first 20 
minutes, every 10 minutes for the next one hour and every hour for the next 6 
hours. 
Sensory block was assessed bilaterally, by analgesia to pinprick with a short 
bevelled hypodermic needle, in mid-clavicular line. The time of onset of 
sensory analgesia was defined as the time taken from the administration of local 
anesthetic to the absence of pin-prick pain at T10 level. 
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Motor block was assessed using modified Bromage scale. 
 0 - No motor block 
 1 - Inability to raise extended legs 
 2 - Inability to flex knees. 
 3 - Inability to flex ankle joints 
Time of onset of motor block was defined as the time to attain a   
Bromage score of 0. 
Sedation was assessed on a four point scale8 
GRADE    DESCRIPTION 
0   Awake and alert 
1   Mildly sedated. 
2   Moderately sedated aroused by shaking. 
3   Deeply sedated difficult to be aroused by  
                          physical stimulation 
 
 Visual analogue pain scale8: Patients were asked to evaluate his/her pain 
on a standard 10 point visual analogue pain scale (VAPS 0 = No pain, VAPS 10 
= Worst possible pain). Sensory analgesia was assessed as per VAPS at 2, 3, 4, 
5, 6 hours postoperatively. Rescue analgesic of 9 ml of 0.25% ropivacaine was 
administered to all the patients in the event of pain (VAPS more than 4). 
Duration of analgesia was calculated from the time of administration of local 
anesthetic drug till the time when rescue analgesic is sought. 
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Duration of surgery: It was the time between the skin incision to the end of 
surgery. 
Complications such as hypotension, bradycardia, nausea & vomiting, 
respiratory depression and shivering were also noted. 
 Hypotension was defined as systolic blood pressure < 90mmHg or >30% 
decrease in baseline values. 
 Bradycardia was defined as heart rate <60/min. 
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STATISTICAL ANALYSIS 
 Statistical analysis and interpretations were performed using PASW 
(Predictive Analysis Software 18). Numerical variables were presented as Mean 
and Standard deviation and categorical variables were presented as frequency 
(%). All continuous variables were analyzed using “student’s independent t 
test”. Discontinuous variable gender was matched by “Chi-square test”. The 
onset of sensory and motor block was analyzed by Kaplan-Meyer survival 
function.  
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OBSERVATION AND RESULTS 
  
 In this study we had encountered 3 failed epidural blocks. Those cases 
were eliminated from the study. Age, sex, preoperative pulse rate and mean 
arterial pressure and duration of surgery between the two groups were 
comparable and were not statistically significant (p>0.05). 
 
Table 1. Comparison of age group between both groups 
 
Age group 
(years) 
Group R Group RM 
Frequency Percentage Frequency Percentage 
20-29 8 26.7 13 43.3 
30-39 4 13.3 6 20.0 
40-49 5 16.7 7 23.3 
50-59 9 30.0 3 10.0 
60-69 4 13.3 1 3.4 
Total 30 100.0 30 100.0 
Mean +/- SD 41.8 +/- 13.9 35.6 +/- 12.2 
Significance p>0.05 
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 The mean age of R group was 41.8 +/- 13.9 years and the RM group was 
35.6 +/- 12.2 years. The difference of mean age between the two groups was 6.2 
years and was not statistically significant (p>0.05). 
 
Figure 1 Comparison of age group between both groups 
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Table 2. Distribution of gender in-between both groups 
Gender 
Group R Group RM 
Total 
Number Percentage Number Percentage 
Male 23 76.7 26 86.7 49 
Female 7 23.3 4 13.3 11 
Total 30 100 30 100 60 
Significance p>0.05 
 
 The above table shows gender wise distribution of R and RM group. The 
two groups were not statistically different in respect of their gender (p>0.05).  
 
Figure 2 Distribution of gender in-between both groups 
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Table 3. Comparison of R and RM group in respect to their preoperative 
pulse rate and mean arterial pressure 
Variable 
Group R Group RM Difference 
of mean 
‘t’ Significance
Mean S.D Mean S.D 
Mean PR 84.9 9.9 89.4 8.5 4.6 1.908 p>0.05 
Mean MAP 80.5 7.4 77.1 7.8 3.4 1.693 p>0.05 
 
 The preoperative pulse rate and mean arterial pressure of both groups 
were compared. The mean pulse rate of R group was 84.9 +/- 9.9 and that of  
RM group was 89.4 +/- 8.5. The difference between the two groups was 4.6 and 
was not statistically significant (p>0.05). Similarly the mean MAP of R group 
was 80.5 and RM group was 77.1 +/- 7.8. The difference between the two 
groups was 3.4 and was not statistically significant (p>0.05). 
Figure 3 
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Table 4. Comparison of duration of surgery in both groups 
Variable 
Group R Group RM Difference 
of mean 
‘t’ 
Significanc
e Mean  S.D Mean S.D 
Duration 
of surgery 
2.9 0.56 2.86 0.41 0.04 0.261 p>0.05 
 
 The duration of surgery between the two groups were compared. The 
mean duration of R group was 2.90 +/- 0.56 hours and the RM group was 2.86 
+/- 0.41 hours. The difference between the two groups was 0.4 and it was not 
statistically significant (p>0.05). 
Figure 4.  Comparison of duration of surgery in both groups 
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Table 5. Comparison of type of surgery in both groups 
Type of surgery Group R 
Group 
RM 
Trendelenberg 5 7 
DHS fixation 5 2 
ORIF- Femur 5 5 
IL nailing- Femur/Tibia 8 7 
Implant exit - Tibia 3 2 
Others 4 7 
 
Figure 5. Comparison of type of surgery in both groups 
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Table 6. Comparison of intra-operative pulse rate of both groups 
Time 
Interval 
Group R Group RM 
‘t’ Significance
Mean S.D Mean S.D 
5 min 93.1 13.0 93.2 7.5 0.660 p>0.05 
15 min 91.5 11.5 90.7 10.3 0.756 p>0.05 
30 min 87.4 9.4 91.1 10.6 1.754 p>0.05 
45 min 86.4 9.6 81.2 10.6 0.653 p>0.05 
60 min 79.4 10.7 79.4 11.0 1.544 p>0.05 
EOS 81.3 13.8 79.9 12.0 1.048 p>0.05 
 
Figure 6. Comparison of intra-operative pulse rate of both groups 
 
 Above table compares the pulse rate of groups intraoperatively at 
different time intervals of 5, 15, 30, 45, 60 minutes and end of surgery and they 
were not statistically significant (p>0.05). 
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Table 7. Comparison of intra-operative MAP of both groups 
Time 
Interval 
Group R Group RM 
‘t’ Significance
Mean S.D Mean S.D 
5 min 79.1 9.5 74.6 9.9 0.741 p>0.05 
15 min 75.9 9.1 70.5 9.4 1.733 p>0.05 
30 min 76.5 7.8 70.2 9.9 0.135 p>0.05 
45 min 72.6 7.0 70.9 8.1 0.035 p>0.05 
60 min 74 7.6 74 7.6 0.432 p>0.05 
EOS 75 6.9 76.8 7.7 0.683 p>0.05 
 
Figure 7. Comparison of intra-operative MAP of both groups 
 
 Above table compares the mean arterial pressure of groups 
intraoperatively at different time intervals of 5, 15, 30, 45, 60 minutes and end 
of surgery and they were not statistically significant (p>0.05). 
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Table 8. Comparison of time of onset of sensory and motor block in both groups 
 
Group R Group RM Difference 
of mean 
‘t’ Significance
Mean S.D Mean S.D 
Sensory 16.9 3.8 14.6 3.6 2.3 2.494 p<0.05 
Motor 18.6 3.8 16.5 2.6 2.1 2.498 P<0.05 
 
 The above table shows the time of onset of sensory and motor block of 
the two groups R and RM. Mean time of onset of sensory of R group was 
16.9+/-3.8min. And the same of RM group was 14.6+/-3.6min with difference 
of mean 2.3 minutes. The result was statistically significant (p<0.05). Similarly 
the time of onset of motor block of R group and RM group were 18.6+/-3.8min 
and 16.5+/- 2.6minrespectively. The difference of mean was 2.1 minutes which 
was statistically significant (p<0.05). 
Figure 8. Comparison of time of onset of sensory and motor block in both groups 
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Figure 9.  Time of onset of sensory block in all patients 
 
 
 
Figure 10.  Time of onset of motor block in all patients 
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Figure 11. Kaplan meir survival curve for time of onset of Sensory block 
in both groups 
 
 
 This is a step line curve showing cumulative survival of all patients in the 
study for the time of onset of sensory block in minutes with R group showing 
time of onset of sensory block in-between 15 minutes for the first patient and 20 
minutes for the last patient. In RM group it was between 18 minutes and 20 
minutes. 
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Table 12. Comparison of duration of analgesia between both groups 
Variable 
Group R Group RM Difference 
of mean 
‘t’ 
Significanc
e Mean  S.D Mean S.D 
Duration 
of 
analgesia 
3.8 0.60 4.0 0.90 0.20 1.181 p>0.05 
 
Figure 12. Comparison of duration of analgesia between both groups 
 
 The above graph shows mean duration of analgesia of R group 3.8 +/- 0.6 
hours and that of RM group 4 +/- 0.9 hours. The difference of mean was 0.2 
hours which was not statistically significant (p>0.05). 
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Two segment regression Time and initial level of block 
Variable Group R Group RM Difference 
of Mean 
Significance
Mean SD Mean SD 
Initial 
level of 
sensory 
block 
T9.80 0.77 T9.95 0.83 0.60 p>0.05 
Time to 2 
segment 
Regression 
(min) 
209.7 60 206.7 40 20 p>0.05 
 
 The above table show the level of initial sensory block and 2 segment 
regression time of the two groups R & RM. Mean level of initial block of R was 
T9.80 and that of RM was T9.95, with difference of mean 0.60; which was 
statistically not significant (p>0.05). 
 Time to 2 segment regression was 209.7 and 206.7 for R and RM group 
respectively. Difference of mean was 20, which was not statistically significant 
(p>0.05). 
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Table 14. Postoperative complications 
 Group R Group RM 
Hypotension 3 2 
Bradycardia Nil Nil 
Nausea & vomiting Nil Nil 
Shivering Nil Nil 
Respiratory depression Nil Nil 
 
 No episode of clinically significant postoperative complication such as 
bradycardia, nausea and vomiting, shivering or respiratory depression were 
noted. 
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DISCUSSION 
 Regional anesthesia is a safe and inexpensive technique with the 
advantage of providing surgical anesthesia and prolonged postoperative pain 
relief. Effective treatment of post-operative pain attenuates autonomic, somatic 
and endocrine responses. Research continues concerning different techniques 
and drugs that could prolong the duration of regional anesthesia and 
postoperative pain relief.  
 Recently the importance of magnesium in anesthetic practice has been 
highlighted. Magnesium is known to be an NMDA receptor antagonist and it is 
assumed that NMDA receptors play an important role in the development of 
central sensitization after noxious peripheral stimulation. Its antinociceptive 
effects in animal and human models of pain have been proved. It is worthwhile 
to further study the role of supplemental magnesium in providing perioperative 
analgesia because this is a harmless molecule, inexpensive and the biological 
basis for its potential antinociceptive effect is promising.3,7 
 There are studies concerning different routes of magnesium 
administration such as intravenous or intrathecally that improve anesthetic and 
analgesic quality. To my knowledge this is the first clinical study that has 
examined the effect of Magnesium as an adjunct to epidural ropivacaine.  
 Tanmoy Ghatak et al8 investigated the effect of addition of magnesium 
sulphate 50 mg as an adjunct to 19 ml of 0.5% bupivacaine  epidurally for 
patients undergoing lower abdominal and lower limb surgeries and  found that 
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the time to achieve T 6 block was 11.80+/-3.21 minutes in magnesium adjuvant 
group and 18.73+/ -2.79 minutes in control group. In the present study the mean 
time to achieve T10 block was 14.6+/-3.6 minutes in the RM group and that of R 
group was 16.9+/-3.8 minutes. They also made an observation that in the 
magnesium group no patients suffered from shivering during the study, whereas 
shivering occurred in four patients belonging to control group. In the present 
study no patients had suffered from shivering in the RM group. 
 Bajwa et al70 compared the effect of epidural ropivacaine and 
ropivacaine clonidine combination for elective cesarean section.20 ml of 0.75% 
ropivacaine was the control group, compared with ropivacaine and clonidine 75 
micrograms as adjunct . The onset time of analgesia, sensory and motor block 
levels were compared and they concluded that the mean time of onset of sensory 
block at T6 level and complete motor block was 15.12 +/- 4.36 minutes and 
21.70 +/- 4.20 minutes respectively. In the present study the mean time of onset 
of T10 and complete motor block was 14 .6+/-3.6minutes and 16.9+/-3.8 minutes 
respectively. The early onset in the control group of their study can be due to 
the effect of pregnancy which alters the onset and spread of epidural blockade71. 
 Birbicer et al9 investigated the effect of addition of 50 mgs of 
magnesium sulphate as an adjunct to caudal ropivacaine 0.25% compared with 
ropivacaine alone on post-operative analgesic requirements, analgesic duration 
and adverse effects. They concluded that the addition of magnesium sulphate as 
an adjuvant to caudal ropivacaine has no beneficial effect. In the present study 
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the duration of analgesia was 3.8+/- 0.6 hours and 4+/-0.9 hours in the R group 
and RM group respectively which was not statistically significant. 
 Bilir et al11 studied the effect of co-administering 50mg of magnesium 
sulphate epidurally as an initial bolus dose followed by a continuous infusion of 
100 mg per day with fentanyl for patients undergoing hip surgery. Although the 
time to first analgesic requirement was slightly longer when magnesium was co-
administered, there was no statistical difference between the two groups (37.1 
vs 51.6 min). No difference between the qualities of sensory or motor block was 
observed. The cumulative fentanyl consumption in 24 hrs was 437 micrograms 
in control group when compared to 328 micrograms in magnesium group. In the 
present study the duration of analgesia was slightly longer in RM group as 
compared to R group but this was not statistically significant.  
     In this study, the dose of magnesium used was based on the reference by 
Buvanendran et al13, a rat model in which 188 micro grams of intrathecal 
magnesium potentiated morphine antinociception. Considering the relative 
difference between human and rat CSF volume and body weight, the 188 
micrograms dose was conservatively extrapolated to 50 mg. No neurological 
findings were reported to be observed in short term about the intrathecal use of 
magnesium at this dose in humans13,72.  It is worth mentioning that there are two 
case reports by Goodman et al68, of having inadvertently administered large 
doses (8.7g, 9.6g) of magnesium into epidural space which did not cause any 
neurological injury.  Lejust et al69 reported an inadvertent intrathecal injection 
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of 1000 mg of magnesium producing a transient motor block followed by a 
complete resolution and no neurological deficit at long term follow up69. 
 One limitation of the study was that serum magnesium and CSF 
magnesium concentration was not measured. However it has been studied that 
most of the total body magnesium (99%) is intracellular and estimation of 
plasma magnesium does not represent magnesium content of the body tissues. 
There is lack of correlation between plasma magnesium concentration and total 
body magnesium content19. 
 Moreover a systematic review of randomized control trials done by 
Lysakowski et al7  showed that, there is no apparent correlation between the 
administered cumulative doses of magnesium and the increase in magnesium 
serum concentration. 
 Another limitation of our study was single dose response evaluation. 
Further studies should address different dosages of magnesium with larger 
number of patients and different surgical settings. 
 It is also possible that epidurally administered magnesium is less effective 
in passing the blood–brain barrier compared to intrathecal route and insufficient 
to achieve the needed CSF concentration. 
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SUMMARY 
 
 Epidural magnesium 50 mg with 0.75% ropivacaine for lower limb 
surgeries shortens the time of onset of sensory and motor blockade with stable 
hemodynamics. There is no effect in prolonging duration of analgesia. No 
significant adverse effects were noted with epidural magnesium. 
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CONCLUSION 
 
 Co-administration of  magnesium as an adjuvant to epidural ropivacaine  
reduces the latency of central neuraxial blockade in adults. The lack of any 
side/adverse effects of epidural magnesium would promote its extensive use in 
the field of regional anesthesia over the years to come.  
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 A COMPARATIVE STUDY BETWEEN EPIDURAL ROPIVACAINE 
WITH MAGNESIUM SULFATE AND ROPIVACAINE  
FOR LOWER LIMB SURGERIES 
 
PROFORMA 
 
Name :  Diagnosis :  
Age :  Nature of 
Surgery 
:  
IP No. :  ASA Grade :  
Blood Group :     
      
      
Pre-operative evaluation     
Pulse :  Airway :  
BP :  CVS :  
RR :  RS :  
   Abdomen :  
      
Pre-operative investigation    
HB% :  Blood Urea :  
BT :  Sr. Creatinine :  
CT :  Chest X-ray :  
RBS :  ECG :  
 
 Preloading IV Infusion of ringer lactate (20ml/Kg) 
Anesthetic Plan  : Epidural Block 
Position  : 
Space   : 
Length of Catheter inside : 
Drug   : 
Group R : 0.75% Ropivacaine (16 ml) + Saline 0.9% (1 ml) 
Group RM : 0.75% Ropivacaine (16 ml) + Magnesium Sulphate 50mg (in 1ml 
0.9% Saline) 
Duration of Surgery : 
 
 Parameters Monitored : 
Time in Min PR MAP SPO2 Sedation 
0     
5     
10     
15     
20     
30     
45     
60     
90     
120     
 
Time of onset of Block  : Sensory   Motor 
Level of initial block - Sensory : 
Two segment regression time: 
Duration of 1st Dose  : 
Time (Hrs) VAPS  
  
  
  
  
  
 
Time of 1st epidural top up  : 
Drug     : 
No. of top up doses in 24 Hrs : 
 Adverse Effects : 
Hypotension  
Bradycardia  
Nausea and vomiting  
Shivering  
Respiratory depression  
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2hrs 3hrs 4hrs 5hrs 6hrs
1 Durai 45 M Implant exit‐ Tibia 1.5 68 82 64 64 60 60 90 78 74 70 70 68 60 70 14 14 T6       200 4.5 3 0 3 4
2 Pandaaram 55 M Implant exit‐ Tibia 3 68 86 60 70 68 68 84 70 74 78 82 80 62 68 10 23 T8       180 5 2 0 2 3 4
3 Muruganathan 45 M Trendelenberg 3 82 76 80 81 88 80 76 90 86 80 78 80 80 72 25 24 T8       190 3 0 0 2 2 3 4
4 Marium 60 F DHS fixation 2.5 84 80 108 100 94 102 90 82 84 82 80 68 74 70 16 16 T6       210 3.45 2 0 3 4
5 Sudalai Mani 25 M DHS fixation 3 84 82 80 82 76 85 83 76 70 78 78 70 68 78 19 24 T6       240 3.45 3 0 2 4
6 Mayandi 50 M Hemiarthroplasty 3 90 94 90 88 80 90 80 94 86 90 88 70 70 68 19 20 T8       220 3.5 2 0 3 4
7 Kumbaiah Devar 60 M ORIF‐ Femur 2 108 88 112 100 92 90 80 88 80 88 84 80 70 72 15 14 T8       200 3 1 2 4
8 Marimuthu 26 M ORIF‐ Femur 3 90 86 90 90 86 78 88 79 74 70 78 60 82 84 16 15 T8       180 4 3 3 4
9 Chinnthambi 55 M ORIF‐ Femur 4 80 78 104 100 98 90 72 60 78 70 70 74 80 77 11 13 T8       210 3.5 4 0 3 4
10 Muthulakshmi 55 F Hemiarthroplasty 3 69 78 110 108 94 86 88 92 88 80 80 78 80 86 10 13 T10      215 4 3 0 2 3 4
11 Arumugam 55 M ORIF‐ BB leg 2.5 80 88 82 80 86 80 60 96 98 92 90 80 78 72 16 16 T10      260 4.3 3 0 0 3 4
12 Kannan 35 M ORIF‐ Femur 3 102 94 102 114 98 85 68 70 94 90 90 80 90 84 19 21 T10      240 4 3 0 3 4
13 Nessammal 55 F DHS fixation 2.5 96 86 98 86 80 80 70 62 70 72 70 68 80 81 17 20 T10      160 3.5 4 0 2 3 4
14 Nagarajan 40 M IL nailing‐ Tibia 3 86 82 90 88 90 98 80 91 72 64 70 80 78 80 19 22 T10      140 3.5 4 0 3 4
15 Palpandi 20 M Implant exit‐ Tibia 2.5 80 74 104 98 98 86 91 90 70 72 70 74 60 78 17 17 T10      180 3.5 3 0 3 4
16 Navamanickaraj 25 M Trendelenberg 3 82 74 90 90 80 78 82 98 78 70 70 78 68 77 17 18 T10      210 4 3 0 2 3 4
17 Parvathy 60 F DHS fixation 4 80 70 80 86 82 88 100 97 78 64 66 69 72 62 19 23 T10      220 3.5 3 0 3 4
18 Murugan 30 M Trendelenberg 3 92 76 100 90 96 90 80 66 72 70 74 70 80 84 24 24 T10      240 4 3 0 2 3 4
19 Kanniappan 51 M IL nailing‐ Tibia 2.5 84 70 100 92 96 90 80 60 62 68 70 78 85 70 21 21 T10      280 5 3 0 2 3 4
20 Esakkimuthu 20 M PFL 2.5 94 64 100 98 89 84 78 96 80 84 83 80 72 68 14 15 T8       215 3 2 0 3 4
21 Sumathi 55 F DHS fixation 3 90 86 90 90 86 80 60 80 74 70 78 76 70 72 16 15 T8       300 3 3 0 2 3 3 4
22 Meeran 30 M Trendelenberg 4 80 76 104 100 98 90 60 100 78 70 70 68 80 90 12 13 T8       280 3.5 4 0 3 4
23 Sugandhi 26 F IL nailing‐ Tibia 3 69 74 110 108 94 95 90 94 88 80 80 60 74 66 10 13 T10      250 4 3 0 0 2 3 4
24 Paramasivan 35 M IL nailing‐ Femur 2.5 80 88 82 80 86 102 86 98 98 92 90 80 78 70 17 18 T10      200 4 3 0 2 3 4
25 Arunachalam 25 M IL nailing‐ Femur 3 102 88 102 114 98 76 60 58 100 90 90 84 80 72 20 21 T10      160 4 3 0 2 3 3 4
26 Sudalai Mani 40 M Trendelenberg 2.5 96 86 98 86 80 100 84 92 70 72 70 60 72 80 18 20 T10      180 3.5 4 0 3 3 4
27 Muthuselvi 40 F IL nailing‐ Femur 3 86 82 90 88 90 100 90 77 72 64 70 64 60 68 20 22 T10      120 4.5 4 0 2 3 3 4
28 Rajan 60 M IL nailing‐ Femur 2.5 80 80 104 98 98 92 86 60 70 72 70 64 68 70 18 19 T10      200 3.5 3 0 2 3 4 4
29 Sivanesh 51 M IL nailng‐ Tibia 3 82 78 90 90 80 90 70 64 78 70 70 68 70 82 18 20 T10      220 4.5 3 0 2 3 4
30 Murukan 25 M ORIF‐ Femur 4 80 68 80 86 82 78 92 80 78 64 66 70 80 80 20 23 T10      190 3.5 3 0 3 4
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31 Muthu 50 M ORIF‐ Femur 70 78 96 80 88 80 84 72 74 60 68 62 70 80 80 20 20 T10      280 5 2 0 1 2 4
32 Subramaniam 48 M Trendelenberg 85 70 90 92 92 86 80 60 70 68 60 64 62 72 72 20 20 T10      210 3.45 3 0 3 4
33 Suresh 20 M ORIF‐ Tibia 82 70 100 96 92 84 80 94 60 60 58 64 70 70 70 18 19 T10      160 4.5 3 0 2 3 4
34 Mani 29 M IL nailing‐ Tibia 94 78 90 98 92 100 94 88 60 68 66 70 68 74 74 20 20 T10      200 6.5 1 0 1 2 3 4
35 Muthukumar 20 M ORIF‐ BB Leg 90 70 92 96 100 88 90 86 72 78 70 66 80 82 82 12 15 T10      210 5 2 0 2 3 4
36 Selvi 26 F ORIF‐ Femur 92 68 96 100 96 84 92 74 68 70 64 70 86 70 70 10 13 T10      115 3.5 3 0 3 4
37 Duraiaragu 44 M LRS Fixation 90 78 104 90 90 92 80 61 74 68 64 64 60 74 74 12 20 T6       220 2 2 0 3 4
38 Kannan 29 M IL nailing‐ Femur 96 68 90 80 86 80 70 94 68 64 60 60 80 76 76 16 19 T10      190 4.5 2 0 2 4
39 Anandh 27 M IL nailing‐ Femur 96 72 92 100 92 78 64 60 68 60 64 62 72 80 80 10 13 T8       170 3 3 0 2 3 4
40 Subbiah 55 M Hemiarthroplasty 78 84 92 89 100 102 80 58 80 70 62 70 68 73 73 17 18 T8       260 3.25 3 0 3 4
41 Vellathai 60 F Hemiarthroplasty 72 74 76 70 80 80 68 92 70 64 74 74 76 78 78 13 15 T8       150 5 2 0 2 3 4
42 Esakkiammal 20 F ORIF‐ Tibia 94 64 98 112 96 80 72 80 56 50 52 72 74 77 77 13 15 T8       140 5 1 0 3 4
43 Kannan 39 M IL nailing‐ Femur 102 74 116 100 96 80 78 86 70 62 68 80 78 76 76 10 13 T10      180 4 3 0 3 4
44 Anandh 21 M ORIF‐ Femur 94 72 96 90 86 74 80 78 70 70 68 70 70 92 92 11 12 T10      190 4 4 0 3 4
45 Dhanashekar 49 M ORIF‐ BB Leg 94 70 98 100 96 80 84 88 80 70 68 70 68 84 84 17 18 T10      200 5 2 0 2 3 4
46 Anandhavel 25 M IL nailing‐ Femur 89 78 94 90 113 80 92 84 76 78 84 80 82 80 80 19 17 T10      210 4 2 0 3 4
47 Gopinath 34 M Trendelenberg 90 74 90 90 92 82 80 90 70 64 68 78 80 70 70 12 15 T10      220 4 2 0 3 4
48 Selvam 22 M LRS Fixation 82 64 82 94 94 78 60 68 60 58 58 68 64 62 62 15 17 T12      300 3 2 0 2 3 4
49 Maharajan 44 M DHS fixation 100 78 88 64 68 60 72 75 68 64 60 62 70 78 78 18 19 T10      310 4 3 0 3 4
50 Arjunan 25 M Trendelenberg 82 72 90 100 98 62 70 80 64 60 62 60 72 90 90 16 16 T10      180 4 3 0 3 4
51 Mohanan 34 M ORIF‐ Femur 82 80 96 98 86 84 70 86 83 74 78 62 78 80 80 13 17 T12      190 5 0 0 2 3 4
52 Mydeen 44 M ORIF‐ Femur 90 88 90 86 80 70 66 90 92 86 88 90 88 80 80 12 15 T10      170 3 2 0 3 4
53 Ayyappan 23 M Trendelenberg 89 90 94 90 78 90 80 98 90 84 78 80 90 86 86 19 20 T10      210 4.5 2 0 2 4
54 Sathyaraj 49 M Trendelenberg 94 84 98 100 118 90 80 60 88 80 80 86 80 74 74 17 18 T10      215 4 2 0 3 4
55 Vijayakumar 23 M Trendelenberg 102 80 96 90 86 78 102 78 86 80 78 70 68 70 70 11 14 T10      200 4 0 0 2 3 4
56 Murukan 34 M Trendelenberg 94 90 96 78 80 60 74 92 84 86 82 80 64 60 60 11 12 T10      260 3 2 0 3 4
57 Muthulekshmi 55 F DHS fixation 94 88 98 96 94 72 90 80 86 80 84 66 70 66 66 14 16 T8       250 5 1 0 2 3 4
58 Kadahari 45 M ORIF‐ Tibia 72 90 76 72 70 70 60 66 84 82 88 84 72 80 80 14 15 T8       180 3 2 0 3 4
59 Arumugam 36 M IL nailing‐ Femur 96 84 92 89 94 101 92 90 88 80 80 72 80 82 82 17 19 T8       240 3.5 3 0 2 4
60 Padmanabhan 39 M IL nailing‐ Femur 96 84 90 92 100 90 98 90 80 76 72 70 80 90 90 11 14 T8       190 3 3 0 2 3 4
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